OR WAIT null SECS
November 02, 2021
Takeda’s acquisition of GammaDelta Therapeutics expands their immuno-oncology and innate immune cell therapy portfolio.
Aceragen’s acquisition of Arrevus adds key treatment candidates to its rare disease pipeline.
Novartis’ scemblix (asciminib) is designed to provide a single treatment option to patients struggling with chronic myeloid leukemia.
November 01, 2021
Abbvie’s Vuity (pilocarpine HCI ophthalmic solution) is the first and only eye drop to receive FDA approval for the treatment of presbyopia.
October 29, 2021
Novavax has filed its COVID-19 vaccine for authorization in the UK and Australia.
Genentech’s Susvimo (ranibizumab injection) is approved for intravitreal use via ocular implant for the treatment of neovascular age-related macular degeneration.
The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.
Merck’s agreement with the Medicines Patent Pool (MPP) aims to facilitate affordable global access for molnupiravir.
October 26, 2021
Moderna’s KidCOVE study showed a robust neutralizing antibody response in children aged six to under 12.
October 22, 2021
Pfizer and BioNTech’s Phase III trial demonstrated 95.6% booster efficacy relative to participants who received placebo.